These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 33622224)

  • 21. Immunoinformatic analysis of structural and epitope variations in the spike and Orf8 proteins of SARS-CoV-2/B.1.1.7.
    Hussain M; Shabbir S; Amanullah A; Raza F; Imdad MJ; Zahid S
    J Med Virol; 2021 Jul; 93(7):4461-4468. PubMed ID: 33704818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of accessory protein variants in the pathogenicity of SARS-CoV-2.
    Hassan SS; Choudhury PP; Dayhoff GW; Aljabali AAA; Uhal BD; Lundstrom K; Rezaei N; Pizzol D; Adadi P; Lal A; Soares A; Mohamed Abd El-Aziz T; Brufsky AM; Azad GK; Sherchan SP; Baetas-da-Cruz W; Takayama K; Serrano-Aroca Ã; Chauhan G; Palu G; Mishra YK; Barh D; Santana Silva RJ; Andrade BS; Azevedo V; Góes-Neto A; Bazan NG; Redwan EM; Tambuwala M; Uversky VN
    Arch Biochem Biophys; 2022 Mar; 717():109124. PubMed ID: 35085577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets.
    Zhang J; Li Q; Cruz Cosme RS; Gerzanich V; Tang Q; Simard JM; Zhao RY
    mBio; 2021 Feb; 13(1):e0016922. PubMed ID: 35164548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
    Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients.
    Maghsood F; Shokri MR; Jeddi-Tehrani M; Torabi Rahvar M; Ghaderi A; Salimi V; Kardar GA; Zarnani AH; Amiri MM; Shokri F
    Pathog Dis; 2022 Feb; 80(1):. PubMed ID: 34994386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases.
    Vojdani A; Vojdani E; Kharrazian D
    Front Immunol; 2020; 11():617089. PubMed ID: 33584709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    PLoS Pathog; 2024 Apr; 20(4):e1011680. PubMed ID: 38635853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
    Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.
    Ita K
    Arch Med Res; 2021 Jan; 52(1):15-24. PubMed ID: 32950264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxysterole-binding protein targeted by SARS-CoV-2 viral proteins regulates coronavirus replication.
    Ma-Lauer Y; Li P; Niemeyer D; Richter A; Pusl K; von Brunn B; Ru Y; Xiang C; Schwinghammer S; Liu J; Baral P; Berthold EJ; Qiu H; Roy A; Kremmer E; Flaswinkel H; Drosten C; Jin Z; von Brunn A
    Front Cell Infect Microbiol; 2024; 14():1383917. PubMed ID: 39119292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).
    Andries J; Viranaicken W; Cordonin C; Herrscher C; Planesse C; Roquebert B; Lagrange-Xelot M; El-Kalamouni C; Meilhac O; Mavingui P; Couret D; Gadea G; Despres P
    Sci Rep; 2022 Apr; 12(1):5999. PubMed ID: 35397679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.